- Home
- CMPO vs OGN Comparison
CMPO vs OGN Comparison
Compare CMPO & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPO
- OGN
- Stock Information
- Founded
- CMPO 2000
- OGN 1923
- Country
- CMPO United States
- OGN United States
- Employees
- CMPO N/A
- OGN N/A
- Industry
- CMPO Finance: Consumer Services
- OGN Biotechnology: Pharmaceutical Preparations
- Sector
- CMPO Finance
- OGN Health Care
- Exchange
- CMPO Nasdaq
- OGN Nasdaq
- Market Cap
- CMPO 2.6B
- OGN 2.7B
- IPO Year
- CMPO N/A
- OGN N/A
- Fundamental
- Price
- CMPO $20.47
- OGN $7.55
- Analyst Decision
- CMPO Strong Buy
- OGN Hold
- Analyst Count
- CMPO 6
- OGN 4
- Target Price
- CMPO $25.17
- OGN $15.75
- AVG Volume (30 Days)
- CMPO 983.6K
- OGN 9.0M
- Earning Date
- CMPO 11-03-2025
- OGN 11-10-2025
- Dividend Yield
- CMPO N/A
- OGN 1.06%
- EPS Growth
- CMPO N/A
- OGN N/A
- EPS
- CMPO N/A
- OGN 1.91
- Revenue
- CMPO $160,683,000.00
- OGN $6,301,000,000.00
- Revenue This Year
- CMPO $10.33
- OGN N/A
- Revenue Next Year
- CMPO $8.81
- OGN $0.65
- P/E Ratio
- CMPO N/A
- OGN $3.94
- Revenue Growth
- CMPO N/A
- OGN N/A
- 52 Week Low
- CMPO $9.24
- OGN $6.18
- 52 Week High
- CMPO $26.78
- OGN $17.23
- Technical
- Relative Strength Index (RSI)
- CMPO 50.14
- OGN 43.82
- Support Level
- CMPO $20.42
- OGN $6.33
- Resistance Level
- CMPO $21.40
- OGN $6.93
- Average True Range (ATR)
- CMPO 1.46
- OGN 0.45
- MACD
- CMPO -0.07
- OGN 0.17
- Stochastic Oscillator
- CMPO 15.52
- OGN 80.29
About CMPO CompoSecure Inc.
CompoSecure Inc is engaged in designing and manufacturing premium financial cards. The Company's metal payment card technology and Arculus security and authentication capabilities deliver premium branded experiences which enable people to access and use their assets, and ensure trust at the point of a transaction. Its products include Metal Cards and Arculus, a digital security platform. It has two reportable segments: Payment Card and Arculus.
About OGN Organon & Co.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.